The Latest Breaking News from Eli Lilly

The once-weekly jab would be offered to diabetic patients alongside diet and exercise,

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer’s medication appears to slow cognitive decline by 35%. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.

The National Institute for Health and Care Excellence (Nice) is judging whether or not the jab would be a good use of NHS funds.

The National Institute for Health and Care Excellence (Nice) is seeing whether the drug would be a good use of NHS funds

Tirzepatide is currently approved by regulators for type 2 diabetes – but may soon also be approved for obesity

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.